Previous 10 | Next 10 |
A COVID-19 vaccine will be worth billions and billions of dollars. It will likely be the most valuable drug on the planet. There are many pharmaceutical companies are pursuing a vaccine, and the market has already started rewarding some of them. Right now the big winners are small-cap biotech va...
Don’t Believe In Penny Stocks? This Might Make You Think Twice What comes to mind when you think about penny stocks ? Low price stock, B.S. companies, or maybe even long-shot lottery tickets? There’s no right or wrong answer to this question but there is an answer to the next qu...
A "black swan" event is a highly unusual, utterly unpredictable happening that throws everybody for a loop. As far as the stock market is concerned, black swans are almost always bad. For instance, 9/11 was a black swan. COVID-19 is a black swan, too. The coronavirus, which did not exis...
Corvus Pharmaceuticals (NASDAQ: CRVS ) +103% on launch immunotherapy study for COVID-19. More news on: Corvus Pharmaceuticals, Inc., Annovis Bio, Inc., Novavax, Inc., Stocks on the move, , Read more ...
Vaxart (VXRT) has soared over 2,000% YTD amid an acceptance to the Russell 3000, joining Operation Warp Speed, and the possibility of an effective COVID-19 'tablet' vaccine. The COVID-19 hype in other small-cap, speculative vaccine players like Novavax ( NVAX ), Inovio ( INO ), and Sorrento Th...
Introduction Vaxart ( VXRT ) is a small cap, clinical-stage biotech company based in South San Francisco, California that develops oral tablet vaccines to protect against infectious diseases caused by coronavirus, norovirus, seasonal influenza, respiratory syntactical virus (RSV), and...
Shares of biopharmaceutical company Emergent BioSolutions (NYSE: EBS) gained 46.6% in the first half of 2020 (January to June), according to data from S&P Global Market Intelligence . The S&P 500 returned negative 3.1% over the period. In 2020, the stock is up 55.9% through ...
If you had bought Novavax (NASDAQ: NVAX) stock at the beginning of the year, you would be a happy investor right now. Shares of this biotech company have skyrocketed by almost 2,000% year to date, a rare feat even within the volatile biotech industry. Novavax has been able to achieve th...
For investors seeking to turn a modest initial investment into millions, explosive growth is desirable. And unexpectedly explosive growth is exactly why many healthcare investors are now looking at the vaccine start-up Vaxart (NASDAQ: VXRT) with newfound appreciation. Vaxart's stock ...
Investors are apparently reacting to Pfizer and BioNTech's release of encouraging preliminary early-stage data on COVID-19 vaccine candidate BNT162b1 that showed significant jumps in neutralizing antibodies compared to convalescent plasma. More news on: AstraZeneca PLC, GlaxoSmithKline p...
News, Short Squeeze, Breakout and More Instantly...
— Cash runway extended into 2026 — — Received one of the largest BARDA-funded Project NextGen Awards to date, up to $453 million — — Company well-capitalized to execute on multiple key clinical and regulatory milestones in COVID-19 and noroviru...
A look at the top 10 most actives in the United States SRIVARU Holding Limited (SVMH) rose 94.8% to $0.2971 on volume of 77,516,058 shares NVIDIA Corporation (NVDA) fell 0.3% to $129.16 on volume of 39,120,242 shares Longeveron Inc. (LGVN) rose 27.0% to $3.415 on volume of 36,214,736 shar...
SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart”) (Nasdaq: VXRT) today announced an underwritten offering of 50,000,000 shares of its common stock at an offering price of $0.80 per share, which is a premium to the last closing price of $0.75 per ...